Preloader Close
I B R A H I M R S E A R C H

We study how disruption of the NAD⁺–PARP1–XRCC1 axis contributes to persistent DNA damage and metabolic stress in ALS. Therapeutic approaches include PARP inhibitors, NAD-boosting agents, and mRNA-LNP delivery to neurons and glia. Our aim is to protect against neuronal death and slow disease progression.

Precision Discovery. On Track to Cure.